The effect of topical diclofenac 3% and calcitriol 3 μg/g on superficial basal cell carcinoma (sBCC) and nodular basal cell carcinoma (nBCC): A phase II, randomized controlled trial

Brinkhuizen, Tjinta; Frencken, Kiki J. A.; Nelemans, Patricia J.; Hoff, Marlou L. S.; Kelleners‐Smeets, Nicole W.J.; Hausen, Axel zur; Horst, Michiel P.J. van der; Rennspiess, Dorit; Winnepenninckx, Véronique; Steensel, M.A.M. van; Mosterd, Klara

doi:10.1016/j.jaad.2016.01.050

Cited by 42 publications

(34 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Combination therapy showed a significant decrease in Ki-67, and complete histologic tumor regression was seen in 43.8% of those with sBCC. However, there were no significant changes in patients with nBCC [61] .…”

Section: Smo Inhibitorsmentioning

confidence: 73%

Biochemical pathways and targeted therapies in basal cell carcinoma: A systematic review

2016

View full text Add to dashboard Cite

Basal cell carcinoma (BCC) is the most common type of human malignancy. It is a slow-growing skin cancer with little ability to metastasize, but it is aggressive and can cause local tissue destruction. Descriptions of Basal Cell Nevus Syndrome (BCNS), characterized by a predisposition to the formation of BCC and other neoplasms, and identification of the genetic defect in this syndrome, has led to significant advancement in our understanding of the pathogenesis of BCC. Unregulated expression of target genes in the sonic Hedgehog (SHH) signaling pathway plays a prominent role in the pathogenesis of BCC. An understanding of the signaling components has allowed for the development of pharmacologic agents that inhibit the SHH pathway. The first inhibitor of the SHH pathway approved by the Food and Drug Administration (FDA) for the treatment of BCC is vismodegib. In this review, we will discuss the biochemical pathways involved in BCC as targets of novel pharmacologic therapies.

show abstract

Section: Smo Inhibitorsmentioning

confidence: 73%

Biochemical pathways and targeted therapies in basal cell carcinoma: A systematic review

2016

View full text Add to dashboard Cite

show abstract

“…Clinical trials have shown that celecoxib may be effective for the prevention of NMSC, including BCCs, in high‐risk skin cancer patients . Result of a recent phase II clinical trial demonstrated that topical diclofenac therapy promotes tumor regression of superficial BCCs and alleviates anti‐apoptotic and proliferative markers …”

Section: Interventionsmentioning

confidence: 99%

“…175 Result of a recent phase II clinical trial demonstrated that topical diclofenac therapy promotes tumor regression of superficial BCCs and alleviates anti-apoptotic and proliferative markers. 176…”

Section: Immunotherapymentioning

confidence: 99%

Basal cell carcinoma pathogenesis and therapy involving hedgehog signaling and beyond

Bakshi

Chaudhary

Rana

et al. 2017

Molecular Carcinogenesis

View full text Add to dashboard Cite

Basal cell carcinoma (BCC) of the skin is driven by aberrant hedgehog signaling. Thus blocking this signaling pathway by small molecules such as vismodegib inhibits tumor growth. Primary cilium in the epidermal cells plays an integral role in the processing of hedgehog signaling-related proteins. Recent genomic studies point to the involvement of additional genetic mutations that might be associated with the development of BCCs, suggesting significance of other signaling pathways, such as WNT, NOTCH, mTOR, and Hippo, aside from hedgehog in the pathogenesis of this human neoplasm. Some of these pathways could be regulated by noncoding microRNA. Altered microRNA expression profile is recognized with the progression of these lesions. Stopping treatment with Smoothened (SMO) inhibitors often leads to tumor reoccurrence in the patients with basal cell nevus syndrome, who develop 10–100 of BCCs. In addition, the initial effectiveness of these SMO inhibitors is impaired due to the onset of mutations in the drug-binding domain of SMO. These data point to a need to develop strategies to overcome tumor recurrence and resistance and to enhance efficacy by developing novel single agent-based or multiple agents-based combinatorial approaches. Immunotherapy and photodynamic therapy could be additional successful approaches particularly if developed in combination with chemotherapy for inoperable and metastatic BCCs.

show abstract

“…Other studies, using variable concentrations, excipients, or other combinations of considered drugs may be profitable in the optimization of new treatments. Thus, although surgical excision is still the best option for all BCC, topical gel diclofenac constitutes an auspicious noninvasive new approach for low-risk superficial BCC [89]. Like diclofenac, piroxicam has been shown to exert antitumorigenic effects.…”

Section: Classical Therapy Of Nmscsmentioning

confidence: 99%

Neoplastic Multifocal Skin Lesions: Biology, Etiology, and Targeted Therapies for Nonmelanoma Skin Cancers

Fernandes

Santos²,

Kovačević³

et al. 2017

Skin Pharmacol Physiol

View full text Add to dashboard Cite

Neoplastic skin lesions are multifocal, diffuse skin infiltrations of particular relevance in the differential diagnosis of ulcerative, nodular, or crusting skin lesions. Nonmelanoma skin cancers (NMSCs), namely, basal cell carcinoma (BCC), squamous cell carcinoma (SCC), and also actinic keratosis (AK), are the most common malignant tumors in humans. BCCs do not proliferate rapidly and most of the times do not metastasize, while SCCs are more infiltrative, metastatic, and destructive. AKs are precursor lesions of cutaneous SCCs. The classical therapy of NMSCs makes use of photodynamic therapy associated with chemotherapeutics. With improved understanding of the pathological mechanisms of tumor initiation, progression, and differentiation, a case is made towards the use of targeted chemotherapy with the intent to reduce the cytotoxicity of classical treatments. The present review aims to describe the current state of the art on the knowledge of NMSC, including its risks factors, oncogenes, and skin carcinogenesis, discussing the classical therapy against new therapeutic options.

show abstract

The effect of topical diclofenac 3% and calcitriol 3 μg/g on superficial basal cell carcinoma (sBCC) and nodular basal cell carcinoma (nBCC): A phase II, randomized controlled trial

Cited by 42 publications

References 27 publications

Biochemical pathways and targeted therapies in basal cell carcinoma: A systematic review

Biochemical pathways and targeted therapies in basal cell carcinoma: A systematic review

Basal cell carcinoma pathogenesis and therapy involving hedgehog signaling and beyond

Neoplastic Multifocal Skin Lesions: Biology, Etiology, and Targeted Therapies for Nonmelanoma Skin Cancers

Contact Info

Product

Resources

About